Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

, MRK

Merck

$62.77

0.11 (0.18%)

18:10
10/09/16
10/09
18:10
10/09/16
18:10

Pfizer reports data on Inlyta-Keytruda, Inlyta-avelumab studies

Pfizer (PFE) announced data from an ongoing, investigational Phase 1b study of INLYTA combined with the checkpoint inhibitor pembrolizumab, a PD-1 inhibitor known as KEYTRUDA and marketed by Merck (MRK), in treatment-naive patients with advanced renal cell carcinoma. Preliminary results from a similar, separate study combining INLYTA with avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody that is being co-developed by Merck KGaA (MKGAY) and Pfizer were also presented. The data suggest evidence of anti-tumor activity for INLYTA in combination with avelumab. Based on these Phase 1 results, two independent global Phase 3 trials evaluating these combinations - INLYTA plus pembrolizumab and INLYTA plus avelumab - each compared with SUTENT in first-line advanced RCC are now enrolling patients. Specifically, early indicators from the A4061079 study point to strong response rates with the INLYTA/pembrolizumab combination, with 37 patients achieving objective responses, including three complete responses and 34 partial responses. 10 patients had stable disease and 5 patients had disease progression. Separately, in the JAVELIN Renal 100 study of INLYTA in combination with avelumab, five out of six patients treated so far had confirmed partial responses -- objective response rate 83.3% -- and one patient with tumor shrinkage not meeting partial response criteria had stable disease.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

MRK

Merck

$62.77

0.11 (0.18%)

MKGAY

Merck KGaA

$35.88

0.1 (0.28%)

  • 25

    Oct

  • 01

    Nov

  • 06

    Nov

PFE Pfizer
$33.56

-0.09 (-0.27%)

08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
MKGAY Merck KGaA
$35.88

0.1 (0.28%)

08/12/16
BREN
08/12/16
DOWNGRADE
BREN
Hold
Merck KGaA downgraded to Hold from Buy at Berenberg

TODAY'S FREE FLY STORIES

KNDI

Kandi Technologies

$3.80

-0.075 (-1.94%)

09:22
04/24/17
04/24
09:22
04/24/17
09:22
Hot Stocks
Kandi Technologies announces receipt of third 2016 subsidy payment for EV sales »

Kandi Technologies Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight Transportation

, SWFT

Swift Transportation

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Upgrade
Knight Transportation, Swift Transportation rating change  »

Knight Transportation…

KNX

Knight Transportation

SWFT

Swift Transportation

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

WING

Wingstop

$28.27

0.175 (0.62%)

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Upgrade
Wingstop rating change  »

Wingstop upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 20

    Jun

TRNO

Terreno Realty

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Hot Stocks
Terreno Realty acquires North Bergen, New Jersey building for $14M »

Terreno Realty acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

09:20
04/24/17
04/24
09:20
04/24/17
09:20
Recommendations
Heico analyst commentary  »

Heico price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Earnings
Upland Software raises FY17 revenue view to $87.0M-$91.0M, consensus $84.18M »

Upland announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees Q2 North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Options
Overnight activity included 387 trades in SPX and 61 trades in VIX »

387 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$103.41

0.77 (0.75%)

09:18
04/24/17
04/24
09:18
04/24/17
09:18
Recommendations
Check Point analyst commentary  »

Check Point price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 12

    Jun

TWTR

Twitter

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Recommendations
Twitter analyst commentary  »

Twitter can beat Q1 but…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Hot Stocks
Upland Software acquires RightAnswers »

Upland Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$96.03

0.02 (0.02%)

09:16
04/24/17
04/24
09:16
04/24/17
09:16
Hot Stocks
Hasbro says has 'right brands, right team' to drive blueprint »

Regarding any potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 18

    May

  • 31

    May

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

, LLTC

Linear Technology

09:15
04/24/17
04/24
09:15
04/24/17
09:15
Upgrade
Analog Devices, Linear Technology rating change  »

Analog Devices upgraded…

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

LLTC

Linear Technology

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HAL

Halliburton

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Hot Stocks
Halliburton says momentum building in North America »

Says believes a bottom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GM

General Motors

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Recommendations
General Motors analyst commentary  »

General Motors Q1 likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

HAL

Halliburton

09:11
04/24/17
04/24
09:11
04/24/17
09:11
Hot Stocks
Halliburton says seeing customers deferring new projects »

Says customers more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

, ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

09:10
04/24/17
04/24
09:10
04/24/17
09:10
Recommendations
Alkermes, Acorda Therapeutics analyst commentary  »

Alkermes 2019 earnings…

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 06

    Jun

  • 08

    Jun

WTKWY

Wolters Kluwer

$41.04

-0.83 (-1.98%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Wolters Kluwer to explore strategic alternatives for Corsearch »

Wolters Kluwer announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$47.06

-0.63 (-1.32%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Halliburton says not chasing market share at cost of pricing »

Says seeing sufficient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GOGO

Gogo

$12.34

0.49 (4.14%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Gogo signs new capacity deal with SES »

SES announced that Gogo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

, SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Technical Analysis
Indexes and Sectors breakout above pivot highs and lows »

The major index ETFs,…

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

TLT

iShares 20+ Year Treasury Bond Fund

XLF

Financial Select Sector

$23.16

-0.24 (-1.03%)

SPY

SPDR S&P 500 ETF Trust

$234.59

-0.75 (-0.32%)

DIA

Diamonds Fund ETF

$205.25

-0.26 (-0.13%)

IWM

iShares Trust Russell 2000 Index Fund

$137.21

-0.31 (-0.23%)

XLV

Health Care Select Sector SPDR

$73.68

-0.44 (-0.59%)

XLE

Energy Select Sector SPDR

$67.79

-0.34 (-0.50%)

XLK

Technology Select Sector SPDR

$53.17

-0.11 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$7.75

-0.38 (-4.67%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Recommendations
Progenics analyst commentary  »

Needham remains a buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Hot Stocks
Adamas: ADS-5012 data confirms reduction in levodopa-induced dyskinesia »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

09:07
04/24/17
04/24
09:07
04/24/17
09:07
Hot Stocks
Amazon launches self-service marketplace for subscription providers »

Amazon.com announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

HRS

Harris

$110.27

0.32 (0.29%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Harris awarded 5-year, $875M ceiling multi-award IDIQ contract by USAF »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.